Ruxolitinib 5 mg tablets

What is Ruxolitinib 5 mg Tablets?

Ruxolitinib 5 mg tablets, sold under the brand Jakavi and generic name Rutinib 5 mg, is a Janus kinase (JAK) inhibitor used to manage conditions like myelofibrosis and polycythemia vera. By specifically targeting JAK1 and JAK2 enzymes, it helps control abnormal blood cell production and reduces inflammation caused by these disorders.

---

How Ruxolitinib Works

Ruxolitinib inhibits JAK1 and JAK2 enzymes, which play a key role in the signaling pathways responsible for excessive blood cell growth and immune system activation. By blocking these pathways:

• Spleen enlargement and discomfort are reduced

• Fatigue and disease-related symptoms improve

• Risk of disease progression is minimized

---

Uses / Indications

• Myelofibrosis: Reduces spleen size, alleviates fatigue, and improves quality of life

• Polycythemia Vera: Controls elevated blood counts and prevents complications

• Other JAK-related disorders: As prescribed by a hematologist

---

Recommended Dose & Administration

• As prescribed by a physician based on the patient’s condition and response

• Tablets should be taken orally with water, with or without food

• Do not crush or chew; swallow whole

---

Benefits of Ruxolitinib 5 mg Tablets

• Targeted therapy: Specifically inhibits JAK1 and JAK2 enzymes

• Symptom management: Reduces fatigue, spleen size, and other disease symptoms

• Disease control: Helps prevent progression of myelofibrosis and polycythemia vera

• Oral convenience: Easy-to-take tablets for daily dosing

---

Side Effects & Precautions

• Common side effects: Headache, dizziness, nausea, mild infections

• Serious side effects (rare): Low blood counts, increased infection risk

• Patients should have regular blood tests during treatment

• Avoid self-adjusting the dose; follow physician instructions

---

Storage & Handling

• Store at room temperature away from light and moisture

• Keep out of reach of children

• Do not use after the expiration date

---

Frequently Asked Questions (FAQs)

1. Who can take Ruxolitinib 5 mg tablets?

   • Adults diagnosed with myelofibrosis or polycythemia vera under a physician’s supervision.

2. Can it be taken with food?

   • Yes, tablets can be taken with or without food.

3. Are regular blood tests necessary?

   • Yes, to monitor blood counts and detect potential side effects.

4. Can it be used long-term?

   • Yes, with regular monitoring and physician guidance.

5. Do I need a prescription?

   • Yes, Ruxolitinib 5 mg tablets (Jakavi / Rutinib) require a medical prescription.